Connect with us

BIOTECH

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Announces Breakthrough with its “Change History” for its Clinical Trial Product for Pancreatic Cancer

Published

on

Biotechnology company Pharmacyte Biotech Inc (OTCMKTS:PMCB) has successfully developed “change history” information and data for CypCaps™ (2nd generation product) compared to CapCell™ (1st generation product). Pharmacyte Biotech uses its signature live-cell encapsulation technology to develop cellular therapies for cancer and diabetes. The breakthrough is a major milestone and a critical component of the company’s Investigational New Drug application (IND). While evaluating the drug and before granting approval, the US. Food and Drug Administration also considers changes to the manufacturing of the two generations of products. PharmaCyte partnered with Austrianova, which provided the required information and data to satisfy cGMP consultant and meet the compatibility requirements by the FDA for the two generations of encapsulated live human cells. Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte said the partnership was especially important in developing the information and data to meet thresholds for regulatory approvals.

CapCell™ and CypCaps™ Generation Product

The company’s first-generation product was called CapCell™”, while the current product is called “CypCaps™.” Although the two products are made from the same cellulose materials, the 2nd generation product requires a material of higher quality. The differences arise with regard to limiting the level of impurities with microbial and endotoxin and heavy metal levels being below limits in the various literature for powdered cellulose. Additionally,  the cellulose is also produced in a more controlled process in the 2nd generation product.

To secure approval from the FDA, companies are required to compare information and data from the same manufactured medicinal product to that of the original product. The two sets of data should be the same. Although improvements are allowed, PharmaCyte’s Phase 2b clinical trial used past data from clinical trials conducted in the 1990s, hence the need to give supporting data and information for the new findings.  There is was an improvement to the final product using the same production process.

There was also a separate set of data for each generation to justify the changes made and how they improved product in the same manufacturing process.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.